DDInter1289 DDInter1082
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Nicotinamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Carbamazepine
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glulisine
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Nicotinamide {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Nicotinamide {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Nicotinamide may cause a minor interaction that can limit clinical effects when taken with Carbamazepine
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Nicotinamide may lead to a major life threatening interaction when taken with Teriflunomide
Nicotinamide may lead to a major life threatening interaction when taken with Leflunomide